Table 3:

Medication and stents

Antiplatelet regimen
    Clopidogrel406 (86.7%)
    Ticlopidine62 (13.3%)
Stents used for treatmenta,b
    Enterprise340 (68%)
    Solitaire (Solo)98 (19.6%)
    Wingspan41 (8.2%)
    LEO16 (3.2%)
    Neuroform5 (1%)

  • ↵a Percentages are obtained over the total number of aneurysms treated (n = 500), whereas others are over the number of patients (n = 468).

  • ↵b Stents with technical failure are not included in this table.